{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Drugs.com Monthly Update Podcast","title":"Drugs.com - Monthly Update January 2026","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/0f6d0439\"></iframe>","width":"100%","height":180,"duration":332,"description":"In our latest episode, we cover the latest approval of Darzalex Faspro for multiple myeloma, age-related near vision loss, and a rare genetic disorder affecting children. We also discuss an extension to the use of Nexplanon, a long-acting birth control, and a simpler transition for those moving from injected to inhaled insulin.Darzalex Faspro (daratumumab and hyaluronidase-fihj) a new approval for use in combination with standard treatments for adults with newly diagnosed multiple myeloma.Yuvezzi (carbachol and brimonidine tartrate), a novel combination eye drop for presbyopia.Zycubo (copper histidinate), the first treatment for Menkes disease in children.Nexplanon (etonogestrel), a birth control implant with an extension of use for up to five years.Afrezza (insulin human), an inhaled insulin, with updated dosing guidance.ChaptersFollow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app","thumbnail_url":"https://img.transistorcdn.com/DIoKA3oI7NY0UzZ45F0V0NkzM-ycfQHBYCciiz9juOc/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mMDAz/YzA5MzEzMjc1MDA5/YjRmMjFmMDA1MjYy/YmZmZC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}